BRBR · BellRing Brands, Inc. · Stock research

Reference close: $10.75 (2026-08-14). All levels below are market levels.

BRBR — BellRing Brands, Inc.

Current Thesis

The $11–12 shelf that this coverage described on 2026-08-08 did not hold. Price went from $11.56 on 2026-08-07 to $10.75 on 2026-08-14, RSI(14) at 27.9, now -74.8% below the $42.68 52-week high. Nothing new was filed or reported in that window — StockTitan's BRBR feed carries no company item after the 2026-08-04 release, and no Form 4 activity surfaced through 2026-08-16. The move is therefore a re-rating on the already-known facts of the print rather than a reaction to fresh news: FY2026 adjusted EBITDA cut to $275–295M from $315–335M, the third reduction to that line this fiscal year, against a raised net-sales guide of $2.335–2.375B.

What remains for an investor is a narrower proposition than the one on offer in July. Demand is intact (Q3 net sales $570.4M, +4.0% YoY, ahead of the $547.762M consensus). The profit damage is itemized: a $10.0M Q3 shake-bottle inventory charge, $21.3M across nine months, $28M of stated full-year impact including roughly $7M of Q4 trade spend. And management named its repair lever on the 2026-08-04 call — a double-digit price increase on Premier shakes plus additional powder pricing, effective in Q1 fiscal 2027, which begins 2026-10-01. That lever is unobservable in reported numbers until the ~mid-November Q4 report and unobservable in results until the Q1 FY2027 print in early February. The interval between now and then contains no dated company event.

Bullish and bearish views on BellRing Brands, Inc.

The model's bull view on BellRing Brands, Inc. (BRBR), in brief: Q3 FY2026 net sales $570.4M, +4.0% YoY (volume +1.7%, price/mix +2.5%), above the $547.762M consensus; FY2026 net-sales guidance was raised to $2.335–2.375B from $2.325–2.365B on 2026-08-04. The bear view: Two consecutive misses against management's own margin guide: ~13% guided into Q2 versus a 9% result; ~16% guided into Q3 versus 13.7%. Both cases follow in full.

Bull Case

• Q3 FY2026 net sales $570.4M, +4.0% YoY (volume +1.7%, price/mix +2.5%), above the $547.762M consensus; FY2026 net-sales guidance was raised to $2.335–2.375B from $2.325–2.365B on 2026-08-04. Company-level price/mix turned positive after a deeply negative Q2 mix quarter.
• Management committed on 2026-08-04 to a double-digit price increase on Premier shakes and additional pricing on powders effective Q1 FY2027 (quarter begins 2026-10-01). This is a direct, dated attack on the 13.7% Q3 margin rather than a cost-savings promise.
• Dymatize net sales +26.7% YoY in Q3 FY2026 on volume +6.0% and price/mix +20.7% — evidence that the portfolio can take price where the brand supports it.
• The margin hit is sized and dated: $10.0M Q3 charge (180bp of margin), $21.3M over nine months, $28M stated full-year impact. Management attributes the bottle write-down to cannibalization by the e-commerce tetra format, a mix shift inside its own demand.
• Seven sell-side targets set between 2026-07-09 and 2026-08-05 — Stephens $20, JP Morgan $17, DA Davidson $15, Stifel $15, Barclays $14, UBS $13.5, TD Cowen $12 — all sit above the 2026-08-14 close of $10.75. Two of those (DA Davidson, TD Cowen) were raised the day after the guide cut.
• $506.9M of repurchase authorization remained at 2026-06-30.
• The three-month return through 2026-08-14 is +10.9%, so the May 2026 trough area near $9.20 (Investing.com 52-week-low report; a 2026-05-15 analyst note referenced a $9.15 share price) has not been retested despite the August guide cut.

Bear Case

• Two consecutive misses against management's own margin guide: ~13% guided into Q2 versus a 9% result; ~16% guided into Q3 versus 13.7%. The FY26 adjusted-EBITDA range was cut roughly 13% in a single quarter on 2026-08-04.
• The core brand is close to flat. Premier Protein net sales +0.7% YoY in Q3 (volume +1.5%, price/mix -0.8%); RTD shakes +1.2% (volume +3.1%, price/mix -1.9%). Taking a double-digit price increase into a line whose price/mix is already negative is an untested elasticity bet.
• Working capital deteriorated: inventories $480.6M at 2026-06-30 versus $330.4M at 2025-09-30, against nine-month net sales of $1,706.4M (+2.3%). Nine-month operating cash flow was $65.0M.
• Long-term debt $1,135.3M against $50.4M cash and a lowered $275–295M FY26 EBITDA guide; stockholders' deficit $(467.2)M at 2026-06-30.
• The buyback ran at an average $27.41 per share across 4.9 million shares for $133.1M in the nine months to 2026-06-30 — capital deployed far above the current market level, which is a fact about timing, not about the remaining $506.9M authorization.
• Michael Axelrod became President and CEO effective 2026-07-29. A new CEO issuing his first full-year outlook in mid-November has an incentive structure that historically favours a conservative reset.

Setup & Price Structure

The narrative is dead. The narrative an investor bought — a single-brand protein compounder with mid-teens margins — failed on measurable grounds, and the structure went with it. Dating it: three reductions to the FY26 adjusted-EBITDA line this fiscal year, the last on 2026-08-04; drawdown of -74.8% from the $42.68 52-week high as of 2026-08-14; and the loss of the $11–12 post-print shelf between 2026-08-07 ($11.56) and 2026-08-14 ($10.75) on no new information. What trades now is a margin-repair and valuation question, not the growth story.

Observables on positioning, without a verdict attached to each:

• The distance between price and published targets widened as price fell. Seven targets $12–$20 (2026-07-09 to 2026-08-05) all sit above $10.75; none has been cut since the 2026-08-04 guide reduction, so published estimates have not yet been marked to the new EBITDA range.
• RSI(14) of 27.9 at the 2026-08-14 close is in oversold territory, reached without a headline in the window.
• No earnings date inside 30 days. The next company-controlled event is fiscal year end 2026-09-30; the next disclosure is the ~mid-November Q4 report. That is roughly three months with no scheduled catalyst.
• No insider Form 4 transactions and no issuance appeared on the tape between the 2026-08-04 print and 2026-08-16.
• The company itself was the marginal buyer at an average $27.41 through 2026-06-30; whether it remained one below $11 is not disclosed until the 10-K.

Structurally, the reference points are the broken $11–12 shelf above and the May 2026 low area near $9.20 below. The stock is between them with no dated event to resolve which side it works toward.

Catalyst Calendar (next 30 days)

• 2026-09-30 — Fiscal 2026 year end. Fixes the balance-sheet date at which the $480.6M inventory build and the stated $28M of FY26 inventory-related actions are struck, and sets the base FY2027 laps. Outside the 30-day window by roughly two weeks.
• 2026-10-01 (est.) — Q1 FY2027 begins; the double-digit Premier shake price increase and powder pricing take effect. First scanner-data read on elasticity follows in the weeks after.
• ~2026-11-17 (est.) — Q4 and full-year FY2026 results plus initial FY2027 outlook. Date unconfirmed; FY2025 Q4 was reported 2025-11-18.

Elapsed catalysts

• No dated company catalyst falls inside the 30 days from 2026-08-16. The gap is real and is part of the setup. (passed 10d ago)

What Would Change Our Mind

The structure already gave up the shelf that held the print, so the first thing that would change the read is the opposite: reclaiming and holding $12 on a weekly basis would say the 2026-08-14 low was liquidation into an oversold tape rather than the start of a leg toward the May area.

Downward, the gradeable condition is a weekly close below $10.40, which abandons the last shelf to survive the 2026-08-04 print and re-exposes the May 2026 low area near $9.20. Secondary conditions that would confirm the reset is open-ended rather than finite: FY2026 adjusted EBITDA reported below the $275M low end at the ~mid-November Q4 print; an initial FY2027 adjusted-EBITDA guide set beneath the $275–295M FY26 range; or the Q1 FY2027 pricing action being deferred, reduced or walked back on that call.

What would rebuild the case: inventories down materially from $480.6M at the fiscal-year-end balance sheet, no new excess-inventory charge beyond the sized $28M, and Premier Protein price/mix turning positive as the increase lands.

Correlation Notes

• Single-brand concentration means BRBR does not track the packaged-food complex closely on fundamentals. Club and mass shelf-reset decisions move the numbers more than aggregate consumer spending does; Premier Protein RTD dominates the mix with no diversification cushion.
• The high-protein consumption theme (GLP-1-adjacent demand) is intact in this company's own data — Q3 volume +1.7%, RTD volume +3.1% — so the stock's drawdown is being driven by unit economics rather than category demand. That decoupling is inference from the segment disclosures, not a measured factor loading.
• Dairy-protein and freight input costs, plus the trade-spend needed to clear bottled-shake inventory, are the operating variables between here and the FY2027 pricing action; none of them publishes on a schedule the equity can trade against before mid-November.
• Sell-side dispersion is wide for a $2.3B-revenue consumer name — $12 to $20 among seven firms in a four-week span — which is itself a statement about how little agreement exists on normalized margin.